Impact of Reimbursement for Biomarker Testing on Clinical PracticeVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”
Dr. S. Yosuf Zafar questions how to incorporate new agents into the standard of cancer care as many of these agents are both expensive and only useful for a small segment of patients.
Alexander Bastian speaks about the need for a sustainable model of pricing as related to cancer treatments and drug development. He talks about indication-based pricing or tumor-based pricing—says that is compelling, but not necessarily possible in the US.